SEC Filing Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals Inc - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of
Madrigal starts rolling submission for NASH drug application with US FDA
Madrigal Pharmaceuticals Inc - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of
Madrigal Pharmaceuticals Inc Trademarks & Logos
MDGL Insider Trading Activity - MADRIGAL PHARMACEUTICALS INC.
Madrigal Shares Skyrocket After Successful NASH Study
SEC Filing NeuroBo Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc - DEF 14A - Proxy Statement - May 01, 2023
MDGL - Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
SEC Filing NeuroBo Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
